Kenneth B Gordon Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

05/2008	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
04/2008	Treating psoriasis with adalimumab.
02/2008	Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
06/2007	Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
04/2007	A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
01/2007	Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
10/2006	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
05/2006	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
04/2006	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
01/2006	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
12/2005	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
09/2005	Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
03/2005	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
12/2004	The efficacy of alefacept in the treatment of chronic plaque psoriasis.
01/2004	Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
12/2003	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
12/2003	Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
12/2003	Remittive effects of intramuscular alefacept in psoriasis.
12/2003	A randomized trial of etanercept as monotherapy for psoriasis.
11/2003	CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
09/2003	Evolution of biologic therapies for the treatment of psoriasis.
08/2003	The immunology of psoriasis and biologic immunotherapy.
05/2002	Biologic therapy for psoriasis: the new therapeutic frontier.

Articles by Research Topic

Disease

23	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2008 - 05/2002
1	Skin Diseases 01/2008
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2007
1	Infection 09/2005
1	Hidradenitis Suppurativa 12/2003
1	Wounds and Injuries (Trauma) 12/2002

Drug/Important Bio-Agent (IBA)

6	efalizumab FDA Link 05/2006 - 12/2003
5	alefacept (Amevive)FDA Link 01/2007 - 11/2003
4	adalimumab (Humira)FDA Link 04/2008 - 01/2004
4	TNFR-Fc fusion protein (etanercept)FDA Link 06/2007 - 12/2003
2	Interleukin-12 (IL 12)IBA 05/2008 - 02/2008
1	infliximab (Remicade)FDA Link 12/2003

Therapy/Procedure

2	Biological Therapy 09/2003 - 05/2002
1	Therapeutics 01/2008
1	Retreatment 04/2006
1	Immunotherapy 08/2003
1	Artificial Skin 12/2002